Concomitant chemoradiotherapy for advanced epidermoid XXXX : a preliminary report.

@entity1 @entity137 @entity5 @entity900 @entity2622 @entity2879 @entity787 @entity1732
BACKGROUND: Because the prognosis of advanced @entity2622 is poor, and has improved very little in the last 20 years, a prospective study was initiated to evaluate the feasibility, response and @entity137 of concomitant chemoradiotherapy for such cervical @entity5 . METHODS: From May 1992 to December 1992, 22 @entity1 entered the study, 21 of them completed the entire treatment. Their ages ranged from 47 to 72 years, median 57. There were 16 FIGO stage IIIB, and 5 stage IIB. Radiotherapy was administered using 1.8 Gy/day, five days a week, to the whole pelvis (50.4 Gy/28 fractions) with or without parametrial boost according to the @entity5 response. Intracavitary brachytherapy 5 Gy x five to six times was given after one or two weeks of rest. Chemotherapy consisted of @entity2879 100 mg/m2 day 1 + @entity900 50 mg/m2 day 1 + @entity1732 25 mg/m2/day day 2-3, repeated every two weeks during external irradiation. RESULTS: All 21 eligible @entity1 achieved complete response, sustaining during a median follow-up time of 12 months. All the initially elevated @entity5 markers (SCC, @entity787 , CA-125) returned to normal range after treatment. The @entity137 was well tolerated. CONCLUSIONS: Concomitant chemoradiotherapy for advanced @entity2622 is both feasible and effective, with acceptable @entity137 . Long-term follow-up is mandatory, and a randomized trial to confirm the superiority of this protocol will be started soon.
